JNJ 18038683

Drug Profile

JNJ 18038683

Alternative Names: JNJ-18038683

Latest Information Update: 04 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Janssen Research & Development
  • Developer Janssen Research & Development; Northwestern University
  • Class Antidepressants
  • Mechanism of Action Serotonin 7 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Bipolar disorders
  • Discontinued Major depressive disorder

Most Recent Events

  • 01 Sep 2015 Phase-II clinical trials in Bipolar disorders in USA (unspecified route) (NCT02466685)
  • 01 Dec 2011 Discontinued - Phase-II for Major depressive disorder in USA (PO)
  • 01 Dec 2008 Janssen Research & Development completes a phase IIa trial in Major depressive disorder in USA (NCT00566202)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top